LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel ; Online: Association of Fructosamine Levels With Glycemic Control in Children With Type 1 Diabetes as Determined by Continuous Glucose Monitoring: Results From the CGM TIME Trial.

    Verbeeten, Kate C / Tang, Ken / Courtney, Jennilea M / Bradley, Brenda J / McAssey, Karen / Clarson, Cheril / Kirsch, Susan / Curtis, Jacqueline R / Mahmud, Farid H / Richardson, Christine / Cooper, Tammy / Lawson, Margaret L

    Canadian journal of diabetes

    2024  

    Abstract: Objective: Our aim in this study was to determine the correlation between serum fructosamine and average blood glucose, as measured by continuous glucose monitoring (CGM) in children with type 1 diabetes.: Methods: Ninety-seven blood samples were ... ...

    Abstract Objective: Our aim in this study was to determine the correlation between serum fructosamine and average blood glucose, as measured by continuous glucose monitoring (CGM) in children with type 1 diabetes.
    Methods: Ninety-seven blood samples were collected from 70 participants in the Timing of Initiation of continuous glucose Monitoring in Established pediatric diabetes (CGM TIME) Trial. Each eligible participant had 3 weeks of CGM data with at least 60% CGM adherence before blood collection. Ordinary least-squares linear regression incorporating restricted cubic splines was used to determine the association between fructosamine levels and mean blood glucose.
    Results: An association was found between fructosamine and mean blood glucose, with an F statistic of 9.543 (p<0.001). Data were used to create a formula and conversion chart for calculating mean blood glucose from fructosamine levels for clinical use.
    Conclusions: There is a complex relationship between average blood glucose, as determined by CGM and fructosamine. Fructosamine levels may be clinically useful for assessing short-term glycemic control when CGM is not available.
    Sprache Englisch
    Erscheinungsdatum 2024-04-16
    Erscheinungsland Canada
    Dokumenttyp Journal Article
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2024.04.007
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Motivational Stage at Continuous Glucose Monitoring (CGM) Initiation in Pediatric Type 1 Diabetes Is Associated With Current Glycemic Control but Does Not Predict Future CGM Adherence or Glycemic Control.

    Verbeeten, Kate C / Chan, Jason / Sourial, Nadia / Courtney, Jennilea M / Bradley, Brenda J / McAssey, Karen / Clarson, Cheril / Kirsch, Susan / Curtis, Jacqueline R / Mahmud, Farid H / Cooper, Tammy / Richardson, Christine / Lawson, Margaret L

    Canadian journal of diabetes

    2021  Band 45, Heft 5, Seite(n) 466–472.e4

    Abstract: Objectives: The Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (CGM TIME) Trial is a multicenter, randomized controlled trial in children with type 1 diabetes, comparing simultaneous pump and CGM with CGM ... ...

    Abstract Objectives: The Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (CGM TIME) Trial is a multicenter, randomized controlled trial in children with type 1 diabetes, comparing simultaneous pump and CGM with CGM initiation 6 months later (Paradigm, Veo, Enlite Sensor, Medtronic Canada). This study addresses the ability of SOCRATES (Stages Of Change Readiness And Treatment Eagerness Scale) to classify children and parents into distinct motivational stages and identify the stages' association with glycated hemoglobin (A1C) at trial entry and outcomes 6 months after CGM initiation.
    Methods: Ninety-eight of 99 eligible children 10 to 18 years of age and 137 of 141 eligible parents completed SOCRATES at trial entry and 6 months later. Parent-child agreement for motivational stage was determined by weighted kappa. Linear regression was used to examine association between motivational stage and i) A1C at trial entry and ii) change in A1C and CGM adherence 6 months after CGM initiation.
    Results: More than 87% of children and 88% of parents were classified into distinct motivational stages, with weak parent-child agreement. At trial entry, motivational stage was associated with A1C, which was 1.02% higher for children in the Action stage than in the Precontemplation stage (p<0.0001). When compared with children of parents in Precontemplation, A1C for children of parents in the Maintenance and Action stages were 0.83% (p=0.02) and 0.36% (p=0.048) higher, respectively. Precontemplation was associated with shorter diabetes duration. Motivational stage at CGM initiation did not predict change in A1C or CGM adherence 6 months later.
    Conclusions: SOCRATES can categorize children with type 1 diabetes and their parents into motivational stages. Although motivational stage was associated with glycemic control at trial entry, it did not predict future diabetes-related behaviour or A1C.
    Mesh-Begriff(e) Adolescent ; Blood Glucose Self-Monitoring/psychology ; Blood Glucose Self-Monitoring/statistics & numerical data ; Child ; Diabetes Mellitus, Type 1/therapy ; Female ; Follow-Up Studies ; Forecasting ; Glycemic Control/statistics & numerical data ; Humans ; Male ; Motivation ; Treatment Adherence and Compliance/statistics & numerical data
    Sprache Englisch
    Erscheinungsdatum 2021-04-21
    Erscheinungsland Canada
    Dokumenttyp Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ISSN 2352-3840
    ISSN (online) 2352-3840
    DOI 10.1016/j.jcjd.2021.04.004
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial.

    Lawson, Margaret L / Verbeeten, Kate C / Courtney, Jennilea M / Bradley, Brenda J / McAssey, Karen / Clarson, Cheril / Kirsch, Susan / Curtis, Jacqueline R / Mahmud, Farid H / Richardson, Christine / Cooper, Tammy / Chan, Jason / Tang, Ken

    Pediatric diabetes

    2020  Band 22, Heft 2, Seite(n) 279–287

    Abstract: Objective: To determine whether timing of CGM initiation offering low glucose suspend (LGS) affects CGM adherence in children and youth starting insulin pump therapy.: Methods: A 5-site RCT of pump-naïve subjects (aged 5-18 years) with type 1 ... ...

    Abstract Objective: To determine whether timing of CGM initiation offering low glucose suspend (LGS) affects CGM adherence in children and youth starting insulin pump therapy.
    Methods: A 5-site RCT of pump-naïve subjects (aged 5-18 years) with type 1 diabetes (T1D) for at least 1 year compared simultaneous pump and CGM initiation offering LGS vs standard pump therapy with CGM initiation delayed for 6 months. Primary outcome was CGM adherence (hours per 28 days) (MiniMed™ Paradigm™ Veo™ system; CareLink Pro™ software) over 6 months after CGM initiation. Secondary outcome HbA1c was measured centrally. Linear mixed-models and ordinary least squares models were fitted to estimate effect of intervention, and covariates baseline age, T1D duration, HbA1c, gender, ethnicity, hypoglycemia history, clinical site, and association between CGM adherence and HbA1c.
    Results: The trial randomized 144/152 (95%) eligible subjects. Baseline mean age was 11.5 ± 3.3(SD) years, T1D duration 3.4 ± 3.1 years, and HbA1c 7.9 ± 0.9%. Six months after CGM initiation, adjusted mean difference in CGM adherence was 62.4 hours per 28 days greater in the Simultaneous Group compared to Delayed Group (P = .007). There was no difference in mean HbA1c at 6 months. However, for each 100 hours of CGM use per 28-day period, HbA1c was 0.39% (95% CI 0.10%-0.69%) lower. Higher CGM adherence was associated with reduced time with glucose >10 mmol/L (P < .001).
    Conclusion: CGM adherence was higher after 6 months when initiated at same time as pump therapy compared to starting CGM 6 months after pump therapy. Greater CGM adherence was associated with improved HbA1c.
    Mesh-Begriff(e) Adolescent ; Blood Glucose/metabolism ; Blood Glucose Self-Monitoring ; Child ; Child, Preschool ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/drug therapy ; Female ; Glycated Hemoglobin A/metabolism ; Humans ; Hypoglycemic Agents/administration & dosage ; Insulin/administration & dosage ; Insulin Infusion Systems ; Male ; Patient Compliance ; Time Factors
    Chemische Substanzen Blood Glucose ; Glycated Hemoglobin A ; Hypoglycemic Agents ; Insulin
    Sprache Englisch
    Erscheinungsdatum 2020-11-04
    Erscheinungsland Denmark
    Dokumenttyp Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1502504-4
    ISSN 1399-5448 ; 1745-1426 ; 1399-543X
    ISSN (online) 1399-5448
    ISSN 1745-1426 ; 1399-543X
    DOI 10.1111/pedi.13144
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Fear of hypoglycemia in children with type 1 diabetes and their parents: Effect of pump therapy and continuous glucose monitoring with option of low glucose suspend in the CGM TIME trial.

    Verbeeten, Kate C / Perez Trejo, Maria Esther / Tang, Ken / Chan, Jason / Courtney, Jennilea M / Bradley, Brenda J / McAssey, Karen / Clarson, Cheril / Kirsch, Susan / Curtis, Jacqueline R / Mahmud, Farid H / Richardson, Christine / Cooper, Tammy / Lawson, Margaret L

    Pediatric diabetes

    2020  Band 22, Heft 2, Seite(n) 288–293

    Abstract: To determine if pump therapy with continuous glucose monitoring offering low glucose suspend (LGS) decreases fear of hypoglycemia among children with type 1 diabetes and their parents. The CGM TIME trial is a multicenter randomized controlled trial that ... ...

    Abstract To determine if pump therapy with continuous glucose monitoring offering low glucose suspend (LGS) decreases fear of hypoglycemia among children with type 1 diabetes and their parents. The CGM TIME trial is a multicenter randomized controlled trial that enrolled 144 children with type 1 diabetes for at least 1 year (mean duration 3.4 ± 3.1 years) starting pump therapy (MiniMed™ Veo™, Medtronic Canada). CGM (MiniMed™ Enlite™ sensor) offering LGS was introduced simultaneously or delayed for 6 months. Hypoglycemia Fear Scale (HFS) was completed by children ≥10 years old and all parents, at study entry and 12 months later. Simultaneous and Delayed Group participants were combined for all analyses. Subscale scores were compared with paired t-tests, and individual items with paired Wilcoxon tests. Linear regression examined association with CGM adherence. 121/140 parents and 91/99 children ≥10 years had complete data. Mean Behavior subscale score decreased from 21.1 (SD 5.9) to 17.2 (SD 6.1) (p < .001) for children, and 20.7 (SD 7.5) to 17.4 (7.4) (p < .001) for parents. Mean Worry subscale score decreased from 17.9 (SD 11.9) to 11.9 (SD 11.4) (p < .001) for children, and 23.1 (SD 13.2) to 17.6 (SD 10.4) (p < .001) for parents. Median scores for 10/25 child items and 12/25 parent items were significantly lower at 12 months (p < .001). Linear regression found no association between HFS scores and CGM adherence. Insulin pump therapy with CGM offering LGS significantly reduced fear of hypoglycemia not related to CGM adherence in children with type 1 diabetes and their parents.
    Mesh-Begriff(e) Adolescent ; Adult ; Blood Glucose Self-Monitoring ; Child ; Child, Preschool ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 1/psychology ; Fear ; Female ; Humans ; Hypoglycemia/etiology ; Hypoglycemia/psychology ; Hypoglycemic Agents/administration & dosage ; Insulin/administration & dosage ; Insulin Infusion Systems ; Male ; Parents/psychology ; Young Adult
    Chemische Substanzen Hypoglycemic Agents ; Insulin
    Sprache Englisch
    Erscheinungsdatum 2020-11-27
    Erscheinungsland Denmark
    Dokumenttyp Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1502504-4
    ISSN 1399-5448 ; 1745-1426 ; 1399-543X
    ISSN (online) 1399-5448
    ISSN 1745-1426 ; 1399-543X
    DOI 10.1111/pedi.13150
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang